Quanta scores $245M to improve dialysis care, AlayaCare closes $225M Series D to expand home healthcare offerings and more digital health fundings

Quanta, a medtech company for dialysis care, has scored a whopping $245 million in its oversubscribed and upsized Series D funding round.

Glenview Capital and Novo Holdings co-led the round. Other participating investors include BlackRock, Eldridge, Sands Capital, Millennium, Monashee Investment Management, Puhua Capital, Segulah Medical and Ancora, Orlando Health, Wellington Partners, btov, Seroba Life Sciences, and The Grands.

“Everybody knows that dialysis care must improve,” John Milad, CEO of Quanta, said in a statement. “For this to happen, providers and physicians need products that allow greater flexibility to bring dialysis directly to the patient, while simplifying complexity and reducing the overall cost of care.

“Our small, simple-to-use, and powerful dialysis system SC+ is positioned to help transform kidney care. The funding we are announcing today will allow us to accelerate our emergence as a significant force in this market.”

The company plans to use the new capital to scale its global operations, specifically focusing on expanding its Beverly, Mass., facility, and growing its leadership team. It’s also preparing to begin a study of its SC+ portable hemodialysis system for in-home use after it was cleared by the FDA for use in acute and chronic care facilities.

AlayaCare, a home healthcare software company, raised $225 million CAD in Series D funding led by Generation Investment Management. Additional participants include Klass Capital, Inovia Capital, CDPQ and Investissement Québec.

The company’s home healthcare software products strive to meet the entire client life cycle from referrals and intake to billing and payroll.

“Our innovative technology helps run the back office more efficiently, allowing care staff to focus on outcomes instead of paperwork,” Adrian Schauer, CEO and founder of AlayaCare, said in a statement.

“Through the support and confidence of our investors, customers, partners and employees, we are excited to scale the AlayaCare platform and take the more sustainable home health-based model mainstream.”

AlayaCare will use the funding to continue global expansion, hire additional staff and invest in new software offerings.

Medical device quality management software company Greenlight Guru has received a strategic growth investment from JMI Equity. The investment was for more than $120 million, according to The Wall Street Journal.

Greenlight Guru develops software specifically for the medical device industry to help companies navigate the regulatory approval process.

The investment will enable accelerated product development, improved product capabilities and global expansion, according to the announcement.

“We listened to the needs of the medical device industry and chose JMI Equity as a strategic partner because they are experts at achieving growth by putting the customer first,” David DeRam, CEO of Greenlight Guru, said in a statement.

“We’ve been extremely deliberate when taking on investment because we wanted to ensure we found the right partner for us and our customers. This partnership will allow us to accelerate the value we provide to our customers as we remain committed to helping medical device companies get their life-changing products to patients and achieve our mission of improving the quality of life.”

Cancer detection technology startup Adela launched this week with $60 million in Series A funding.

F-Prime Capital led the round with additional support from OrbiMed, Deerfield Management, Decheng Capital and RA Capital Management.

The Toronto-based company’s platform uses genome-wide methylation analysis technology for early detection of cancer. At launch, the technology will be used for cancer detection, diagnosis and management, but the company plans to expand into other diseases in the future.

Adela will use the funding to support the commercialization of its technology.

Bicycle Health, a virtual provider of opioid use disorder treatment, closed a Series A investment round worth $27 million led by Questa Capital. City Light Capital, Emily Melton and previous investor SignalFire also participated in the raise.

The company provides personalized treatment plans that include medication-assisted treatment (MAT) and behavioral health teletherapy in over 20 US states. Bicycle Health’s services are also now nationally covered by UnitedHealthcare, Aetna, Medicare and are covered in select locations by Medicaid Cigna and Blue Cross Blue Shield.

“Since COVID-19 hit, patients with opioid use disorder have really suffered,” Ankit Gupta, Bicycle Health CEO and founder, said in a statement. “OUD is up 29%, in-person clinics have shut down and 40% of counties in the US have no opioid use disorder provider. Our mission is to provide confidential, convenient and affordable whole-person care to anyone who needs help.”

The new cash will go towards growing its clinician network, partnering with payers and conducting research into OUD.


Source link


The leading source for trustworthy and timely health and medical news and information. Providing credible health information, supportive community, and educational services by blending award-winning expertise in content, community services, expert commentary, and medical review. Everything about health is here with the difference of Dr.About

Related Articles

Leave a Reply

Back to top button